Low FST expressions significantly correlated with reduced overall survivals (Fig. 1c, e, g, log-rank p < 0.05) and relapse-free survivals (Fig. 1d, f, h, log-rank p < 0.05) in patients with HR-positive BC, HER2-positive BC, or TNBC. This evidence concerns the gene ERBB2 and breast cancer.